Saniona (SANION) Corporate presentation summary

Company overview and financial position

• Focuses on neurological and psychiatric diseases with a partnership-driven business model.

• Listed on NASDAQ Stockholm with a market cap of 2.6 BSEK ($285M) and strong cash reserves of 581 MSEK ($64M) at year-end 2025.

• Holds 820 MSEK ($90M) in total assets, including near-term milestones and property.

Strategic pillars and market opportunity

• Deep expertise in ion-channel drug discovery, validated by multiple collaborations and licensing deals.

• Well-positioned to benefit from renewed industry interest in CNS disorders.

• Targets high unmet needs in epilepsy and depression, which represent significant healthcare costs in the EU.

Pipeline and clinical development

• Three prioritized assets: SAN2668 (paediatric epilepsy), SAN2219 (refractory focal epilepsy), SAN2465 (MDD/TRD), all advancing toward Phase 1 in late 2026.

• Each asset is designed for subtype-selective GABA modulation to maximize efficacy and minimize side effects.

• Additional partnered programs: ACP-711 (essential tremor, with Acadia) and SAN2335 (epilepsy, with Jazz Pharmaceuticals).